OakChart

GT Biopharma Inc

GTBPHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

3.95-0.01 (-0.25%)
2026-11-12 03:33 CET
Market cap
8.14 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-32.76 USD m
Free cash flow, TTM
-14.43 USD m
EPS diluted, TTM
-90.07
P/E
-
Compare

Price

GTBP against its 20, 50 and 200-day averages
2050200earnings
5.0010.0015.00295K590KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GTBPclose 3.9520-day 5.4150-day 6.31200-day 9.213.95

86.3% under the 52-week high of 28.75 on 14 Nov 2025. 52-week low 3.86 on 11 Nov 2026. Last 15 sessions, 49.9% high to low

Volume 0.41× normal · the line is the 50-bar volume average

Profile

GTBP
52-week range, 0% of the way up
3.8828.75

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE and Dual Targeting TriKE platforms. Its product candidates include GTB-3650, a CD33-targeted therapy for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, and GTB-5550, a B7-H3-targeted therapy for solid tumors. The company was founded in 1965 and is headquartered in San Francisco, CA.

Employees1
IPOMar 17, 1980
Beta0.86
ATR, 14d0.54
Rel volume0.41
Short float14.25%
Insider own16.00%
Inst own5.29%

Snapshot

6 groups

Valuation

Index-
Market Cap8.14M
Enterprise Value3.09M
Income-32.76M
Sales0.00M
Book/sh2.00
Cash/sh2.45
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1
IPOMar 17, 1980

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.98
P/C1.61
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.38
Current Ratio2.38
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-90.07
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y31.76% 49.68%
Sales past 3/5Y- -
EPS Y/Y TTM75.09%
Sales Y/Y TTM-
EPS Q/Q98.92%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.-50.00% -

Ownership

Insider Own16.00%
Insider Trans0.00%
Inst Own5.29%
Inst Trans3.35%
ROA-342.05%
ROE-1446.48%
ROIC-618.74%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-27.05%
SMA50-37.36%
SMA200-57.09%
Trades-

Technical

Shs Outstand1.79M
Shs Float1.73M
Short Float14.25%
Short Ratio3.47
Short Interest0.25M
52W High28.75 -86.26%
52W Low3.88 1.80%
Volatility10.28% 9.76%
ATR (14)0.54
RSI (14)31.61
Beta0.86
Rel Volume0.41
Avg Volume70.95K
Volume28,970

Performance

Perf Week-18.39%
Perf Month-39.23%
Perf Quarter-46.87%
Perf Half Y-49.47%
Perf YTD-79.88%
Perf Year-76.62%
Perf 3Y-97.76%
Perf 5Y-99.90%
Perf 10Y-100.00%
Recom1.00
Target Price75.00
Prev Close3.96
Price3.95
Change %-0.25%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Dec 02, 2024InitiatedRROTH MKMBuy$11+178.5%
May 24, 2021InitiatedHH.C. WainwrightBuy$25+532.9%
Apr 13, 2021InitiatedRB. Riley SecuritiesBuy$21+431.6%
Mar 17, 2021InitiatedRROTH CapitalBuy$25+532.9%

Peers

Mkt cap
TickerCompanyMkt cap
ATNMActinium Pharmaceuticals Inc49.99M
CNTXContext Therapeutics Inc19.85M
GDTCCytoMed Therapeutics Ltd9.94M
INMBINmune Bio Inc34.05M
MBRXMoleculin Biotech Inc8.50M
NKTXNkarta Inc106.12M
JANXJanux Therapeutics Inc758.06M
CUECue Biopharma Inc135.55M
ARTVArtiva Biotherapeutics Inc201.19M
KURAKura Oncology Inc687.66M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting (GlobeNewswire)
  • GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting (GlobeNewswire) -7.14%
  • GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma (GlobeNewswire) -22.61%
  • GT Biopharma to Host Live Company Presentation on the Development of TriKE Platform for Cancer Treatment, September 11, 2026 (GlobeNewswire) +39.32%
  • GT Biopharma Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
  • A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire) +11.30%
  • GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives (GlobeNewswire) -7.57%
  • The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire) +7.36%
  • Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire) +18.03%
  • B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic (PR Newswire) -7.51%
  • GT Biopharma Reports First Quarter 2026 Financial Results (GlobeNewswire) -10.25%
  • GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors (GlobeNewswire) +40.36%
  • GT Biopharma to Participate in the 38th Annual Roth Conference (GlobeNewswire) +5.67%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-3.000-2.000-0.000.001
2026Q12026-05-18-2.750-2.750-2.7810.000.001
2025Q42026-03-02-55.500-5.500-110.330.000.001
2025Q32025-11-04-20.750-9.50025.9920.000.001
2025Q22025-08-06-13.750-17.000-272.880.000.001
2025Q12025-05-19-8.250-8.250-8.2730.000.001
2024Q42025-02-21-41.750-38.750-42.2390.000.001
2024Q32024-10-29-38.250--38.1660.00--
2024Q22024-08-14-54.250--54.1780.00--
2024Q12024-05-15-41.000--41.0320.00--
2023Q32023-11-01-45.000-63.750-44.175--2
2023Q22023-08-07-41.263-75.000-37.193--2
2023Q12023-05-15-7.500-108.75-4.3580.000.002
2022Q42023-03-30-135-131.25-127.990.000.002
2022Q32022-10-31-165-82.500-164.460.000.002
2022Q22022-08-11-75.000-131.25-71.5280.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-3,320-225-4,8400.000.00
2021FY-1,545-1,360-1,5450.000.00
2022FY-495-491.25-491.50.00-
2024FY-173.5-169.75-173.420.000.00
2025FY-167-41.500-0.000.00
2026FY--10.750--0.00
2027FY--8.000---
2028FY--7.000---
2029FY-0.250--20.07
2030FY-7.500--59.88

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-141000.000.000.00
2026Q3S2026-05-181000.000.000.00
2026Q3S2026-03-021000.000.000.00
2026Q3E2026-10-28100-2.50-2.50-2.50
2026Q3E2026-08-14101-2.50-2.50-2.50
2026Q3E2026-05-18100-2.00-2.00-2.00
2026Q3E2026-03-02100-2.00-2.00-2.00
2026Q2S2026-05-181000.000.000.00
2026Q2S2026-03-021000.000.000.00
2026Q2E2026-08-14101-0.12-0.12-0.12
2026Q2E2026-05-18100-0.08-0.08-0.08
2026Q2E2026-03-02100-0.08-0.08-0.08
2026Q1S2026-03-021000.000.000.00
2026Q1E2026-05-14101-0.11-0.11-0.11

Estimate history

EPS, annual-109618.508-65776.74-8565.578-4839.518-1545.33-491.498-140.925-173.424-156.21-90.073
Period201720182019202020212022202320242025TTM
EPS, quarterly-54.178-38.166-42.239-8.273-272.87725.992-110.326-2.781-2.957
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0040.0040.0050.0070.0430.0440.0550.0891.0211.787
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0890.0890.0890.1010.1310.2421.0211.4071.787
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.000.01
Gross Profit0.000.000.000.000.000.000.00-0.00-0.01
Selling, General and Administrative Excl. Other16.3412.4214.3613.5821.2657.526.7611.4521.55
Research and Development3.483.475.806.478.819.590.481.679.07
Other Operating Expense0.000.000.000.000.000.240.000.000.00
Operating Income-16.34-12.42-14.36-13.58-21.26-57.76-6.76-11.46-21.55
Interest Expense0.250.130.000.000.010.723.322.139.12
Unusual Expense-23.07-12.65-0.80-5.39-0.09-0.1817.984.60228.51
Net Income Before Taxes-22.08-28.35-13.16-7.60-20.88-58.01-28.30-38.65-259.19
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-22.08-28.35-13.16-7.60-20.88-58.01-28.30-38.65-259.19
Net Income From Continuing Operations-22.08-28.35-13.16-7.60-20.88-58.01-28.30-38.65-259.19
Net Income-32.76-34.45-13.16-7.60-20.88-58.01-28.30-38.65-259.19
EPS (Recurring)-31.50-196.37-180.80-210.94-492.96-1,548.72-2,686.65-7,852.02-25,181.63
EPS (Basic, Before Extraordinaries)-90.07-156.21-173.42-140.93-491.50-1,545.33-4,839.52-8,565.58-65,776.74
EPS (Diluted)-90.07-156.21-173.42-140.93-491.50-1,545.33-4,839.52-8,565.58-65,776.74
EBITDA-16.34-12.42-14.36-13.58-21.26-57.76-6.76-11.45-21.55
Non-Operating Income (Expense)-28.56-28.460.400.590.290.04-0.23-20.460.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.520.430.232.204.6217.230.27-9.10
Shares Outstanding1.791.020.090.060.040.040.010.010.00
Market Capitalization8.148.146.8110.5628.7997.7937.615.6532.92

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other4.512.855.593.381.511.933.763.60
Research and Development1.050.411.380.630.361.101.931.31
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.51-2.85-5.59-3.38-1.51-1.93-3.76-3.60
Interest Expense0.060.060.130.000.000.000.000.00
Unusual Expense0.00-0.01-11.41-11.640.11-1.120.07-0.10
Net Income Before Taxes-4.52-2.83-23.038.30-30.17-0.78-3.77-3.41
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.52-2.83-23.038.30-30.17-0.78-3.77-3.41
Net Income From Continuing Operations-4.52-2.83-23.038.30-30.17-0.78-3.77-3.41
Net Income-4.59-3.37-28.904.10-30.25-0.78-3.77-3.41
EPS (Recurring)-2.96-2.79-140.82-25.72-272.16-16.66-41.68-38.93
EPS (Basic, Before Extraordinaries)-2.96-2.78-110.3325.99-272.88-8.27-42.24-38.17
EPS (Diluted)-2.96-2.78-110.3325.99-272.88-8.27-42.24-38.17
EBITDA-4.51-2.85-5.59-3.38-1.51-1.93-3.76-3.60
Non-Operating Income (Expense)0.060.07-28.720.04-28.540.030.060.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.050.050.050.380.000.000.010.00
Shares Outstanding1.791.411.020.240.130.100.090.09
Market Capitalization8.1414.3620.053.5511.725.456.815.16

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments6.914.0413.9716.5131.985.300.030.060.58
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.570.190.080.050.190.360.250.030.00
Total Current Assets7.474.2314.0616.5632.175.660.270.090.58
Net Property, Plant & Equipment0.000.000.050.170.000.000.110.040.01
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.0025.26253.78
Other Assets0.630.000.000.010.000.000.010.010.01
Total Assets8.114.2314.1116.7432.175.660.4025.40254.37
Short Term Debt Incl. Current Port. of LT Debt0.000.000.060.110.0326.3313.3610.800.03
Accounts Payable0.753.854.333.148.192.241.941.762.55
Other Current Liabilities1.572.052.251.692.046.524.411.460.10
Total Current Liabilities2.325.906.634.9410.2635.0919.7114.032.68
Long Term Debt0.000.000.000.060.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities2.325.906.635.0010.2635.0919.7114.032.68
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity5.79-1.677.4711.7321.91-29.27-19.1411.54251.86
Total Shareholders Equity5.79-1.677.4811.7321.91-29.26-19.1411.54251.86
Accumulated Minority Interest0.000.000.000.000.00-0.17-0.17-0.17-0.17
Total Equity5.79-1.677.4811.7321.91-29.43-19.3111.37251.69
Total Liabilities & Stockholders Equity8.114.2314.1116.7432.175.660.4025.40254.37
Book Value Per Share5.66-18.70135.35268.92512.50-4,206.58-3,497.702,904.1564,072.10
Tangible Book Value Per Share5.66-18.70135.35268.92512.50-4,206.58-3,497.70-3,454.93-488.70
Full-Time Employees112283235
Price to Book Ratio1.98-4.081.061.804.46-1.29-0.302.850.87
Return on Assets-459.62-143.53-49.26-85.41-306.70-934.32-299.65-185.29-113.35
Return on Equity-1,377.41-453.39-79.09-124.15----196.80-123.70
Return on Invested Capital-489.96--101.62-177.01-264.78---2,246.17-57.24
Quick Ratio3.220.722.123.353.140.160.010.010.22
Current Ratio3.220.722.123.353.140.160.010.010.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-4.76-28.35-13.16-7.60-20.88-58.01-28.30-38.65-259.19
Depreciation------0.000.000.01
Other Funds (Non Cash)-11.1416.36-0.57-3.087.6634.4718.6332.05248.39
Funds from Operations-15.90-11.99-13.73-10.68-13.23-23.55-9.67-6.60-10.79
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.47-0.920.831.82-1.997.942.402.940.11
Cash from Operating Activities-14.43-12.91-12.90-8.85-15.22-15.61-7.26-3.66-10.68
Capital Expenditures0.000.000.000.000.000.000.000.00-0.04
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.20-
Purchase or Sale of Investments0.000.0012.89-2.0112.14-23.040.000.000.00
Purchase of Investments0.000.000.00-2.010.00-23.040.000.000.00
Sale Or Maturity of Investments0.000.0012.890.0012.140.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.0012.89-2.0112.14-23.040.000.20-0.04
Cash Dividends Paid-0.23-0.230.000.000.000.000.000.000.00
Change in Capital Stock14.3916.002.986.270.0041.110.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock14.3916.002.986.270.0041.110.000.000.00
Proceedsfrom Stock Options9.3710.512.986.270.0024.680.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.001.2112.533.4310.73
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.220.000.000.000.00
Other Financing Activities Uses0.000.000.000.00-0.220.000.000.000.00
Cash from Financing Activities14.1615.782.986.27-0.2242.3212.533.4310.20
Net Change in Cash-0.272.862.96-4.59-3.303.675.27-0.03-0.52
Free Cash Flow-14.43-12.91-12.90-8.85-15.22-15.61-7.26-3.66-10.71
Preferred Dividends (Cash Flow)--0.23-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments5.059.026.912.625.322.46
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.230.410.570.941.040.20
Total Current Assets5.289.437.473.566.362.66
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.510.570.630.760.760.00
Total Assets5.7910.008.114.327.122.66
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable1.020.250.750.771.372.38
Other Current Liabilities1.202.161.570.5529.671.26
Total Current Liabilities2.222.422.321.3231.043.64
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.222.422.321.3231.043.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.001.960.00
Common Equity3.577.585.793.00-25.88-0.98
Total Shareholders Equity3.577.585.793.00-23.92-0.98
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3.577.585.793.00-23.92-0.98
Total Liabilities & Stockholders Equity5.7910.008.114.327.122.66
Book Value Per Share2.005.395.6612.39-197.65-9.67
Tangible Book Value Per Share2.005.395.6612.39-197.65-9.67
Full-Time Employees--1---
Price to Book Ratio1.981.893.471.18-0.45-5.56
Return on Assets-342.05-754.45-740.43-476.91-465.27-185.71
Return on Equity--1,446.48-2,218.95-1,036.73--538.87
Return on Invested Capital-126.59-37.37-397.98276.63--
Quick Ratio2.383.903.222.700.210.73
Current Ratio2.383.903.222.700.210.73

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.52-2.83-5.718.30-30.17-0.78
Other Funds (Non Cash)0.050.040.05-11.2727.70-0.12
Funds from Operations-4.47-2.80-5.66-2.97-2.47-0.90
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.210.331.64-0.71-0.55-1.30
Cash from Operating Activities-4.26-2.47-4.02-3.68-3.01-2.20
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.00-0.14-0.090.000.00
Preferred Dividends (Cash Flow)---0.14---
Change in Capital Stock0.304.588.451.065.880.62
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.304.588.451.065.880.62
Proceedsfrom Stock Options0.304.004.001.064.830.62
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.304.588.300.985.880.62
Net Change in Cash-3.962.114.28-2.702.86-1.59
Free Cash Flow-4.26-2.47-4.02-3.68-3.01-2.20

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.25%0.2M1.7M64.46K
2026-10-1516.12%0.3M1.7M54.75K
2026-09-3014.91%0.3M1.7M56.17K
2026-09-1516.88%0.3M1.5M55.88K
2026-08-319.04%0.2M1.7M36.32K
2026-08-149.53%0.2M1.7M48.39K
2026-07-319.35%0.2M1.7M59.47K
2026-07-1511.42%0.2M1.7M61.40K
2026-06-3024.69%0.1M0.6M56.73K
2026-06-159.35%0.1M1.1M51.48K
2026-05-295.68%0.1M1.4M46.02K
2026-05-155.90%0.1M1.4M40.08K
2026-04-302.20%0.0M1.1M36.58K
2026-04-152.44%0.0M1.1M37.44K
2026-03-312.72%0.0M1.1M47.54K
2026-03-133.71%0.0M1.1M62.56K
2026-02-277.60%0.1M1.1M63.83K
2026-02-1311.33%0.1M0.9M71.20K
2026-01-3029.06%0.1M0.4M61.51K
2026-01-1526.19%0.1M0.4M59.78K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-20EFFECTEffectiveness filing by commission orderSEC
2026-10-20424B3SEC
2026-10-13DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-13SEC
2026-10-09S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-10-02PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-02SEC
2026-09-29DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-258-KCurrent report2026-09-22SEC
2026-09-218-KCurrent report2026-09-18SEC
2026-09-158-KCurrent report2026-09-14SEC
2026-09-15SCHEDULE 13GSEC
2026-09-038-KCurrent report2026-09-02SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-02DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-02SEC
2026-06-18PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-06-128-KCurrent report2026-06-08SEC
2026-05-228-KCurrent report2026-05-20SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-13EFFECTEffectiveness filing by commission orderSEC
2026-05-13424B3SEC
2026-05-11CORRESPSEC
2026-05-06UPLOADUpload SubmissionSEC
2026-04-30S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-04-078-KCurrent report2026-04-03SEC
2026-03-0610-Q/A2025-06-30SEC
2026-03-0610-Q/A2025-09-30SEC
2026-03-0210-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-028-KCurrent report2026-03-01SEC
2026-01-30EFFECTEffectiveness filing by commission orderSEC
2026-01-30424B3SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC0.89%
GEODE CAPITAL MANAGEMENT, LLC0.57%
VANGUARD FIDUCIARY TRUST CO0.53%
UBS Group AG0.30%
HRT FINANCIAL LP0.25%
Allworth Financial LP0.25%
Everhart Financial Group, Inc.0.24%
Arax Advisory Partners0.22%
Opal Wealth Advisors, LLC0.19%
NORTHERN TRUST CORP0.18%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.89%
Fidelity Extended Market Index Fund0.37%
Fidelity Series Total Market Index Fund0.14%
Fidelity Total Market Index Fund0.00%
Guggenheim Active Allocation Fund0.00%

OakChart. GTBP. Cached 15 minutes.

Some panels did not load: insider.